


Emergency A Malaysia 97 vaccine protects against A/Asia/G-VII (A/IRN/22/2015)

Vosloo, Wilna¹; Dekker, Aldo²; Sanz-Bernardo, Beatriz³; Eble, Phaedra²; Horsington, Jacquelyn; Ludi, Anna³; King, Donald³ & Singanallur, Nagendrakumar¹

¹CSIRO Australian Animal Health Laboratory, Australia


²Wageningen Bioveterinary Research, The Netherlands

³The Pirbright Institute, United Kingdom



CSIRO HEALTH & BIOSECURITY / AUSTRALIAN ANIMAL HEALTH LABORATORY

www.csiro.au




Westward movement of A/Asia/G-VII (G18)

- Widespread outbreaks in the Middle East and Caucasus
 - Iran, Saudi Arabia, Turkey and Armenia reporting major outbreaks and apparent vaccine failures

A/ASIA/G-VII reported cases

- BAN/GA/Sa-197/2013
- BAN/CH/Ra-15/2012
- BAN/GA/To-02/2012
- IND/21/90
- IND/256/98
- IND/161/97
- IND/432/97
- IND/119/2000
- IND/10/2000
- IND/67/2000
- IND/81/2000
- IND/96/96
- IND/299/94
- IND/433/01
- IND/144/03
- IND/24/03
- IND/30/03
- IND/153/03
- IND/163/03
- IND/270/03
- IND/245/2007
- IND/17/2009
- A/SAU/1/2015
- A/IRN/22/2015
- A/ARM/1/2015
- A/Van/TUR/203/2015




Vaccine matching studies at TPI

	Field Virus	A/SAU/1/2015	A/SAU/2/2015	A/SAU/19/2016	A/IRN/8/2015	A/IRN/12/2015	A/IRN/22/2015	A/IRN/25/2015	A/IRN/8/2016	A/SAU/24/2016	A/SAU/41/2016	A/EGY/19/2016	A/BHU/03/2017
Vaccine Virus	A/IRN/05	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	A22/IRQ	0.11	0.11	0.08	0.13	0.04	0.20	0.00	0.13	0.12	0.22	0.17	0.11
	A/MAY/97	0.14	0.23	-	0.23	0.15	-	-	-	-	-	-	-
	A/TUR/20/06	0.03	0.06	0.00	0.00	0.15	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	A/SAU/95	0.20	0.17	0.22	0.26	0.11	0.25	-	-	-	-	-	-
	A/IRN/87	0.00	0.04	-	-	-	-	-	-	-	-	-	-
	A/IRN/96	0.04	0.06	-	-	-	-	-	-	-	-	-	-
	A/IRN/99	0.00	0.00	-	-	-	-	-	-	-	-	-	-
	A/IND/40/2000	0.26	-	-	-	0.24	-	-	0.03	-	-	-	-
	A TUR 11	0.01	-	-	-	0.04	-	-	0.10	-	-	-	-
	A TUR 14	0.00	-	-	-	0.00	-	-	0.00	-	-	-	-
	A ERITREA	-	-	-	-	-	-	-	-	-	-	-	0.21

Vaccine efficacy study by the TPI

- Commercial polyvalent vaccine, incorporating 7 different strains of serotypes O, Asia-1, SAT-2 and serotype A (A/IRN/05 and A/SAU/95)
- Partial protection in a modified PPG test (56% protection i.e. ~ 1 PD₅₀/dose)




Pilot study with A22/IRQ and A/MAY/97 vaccines

- A22/IRQ ($r_1 \sim 0.1$)
- A/MAY/97 ($r_1 \sim 0.2$)
- Two groups of vaccinated cattle
 - 7 for each vaccine (3 controls)
 - Challenged IDL at 21 dpv
- A/MAY/97 – 5/7 protected ($\sim 70\%$)
- A₂₂/IRQ – 2/7 protected ($\sim 30\%$) ($p=0.286$)
- Viraemia only in UV controls ($p=0.16$)




A/MAY/97

A22/IRQ





Unvaccinated controls

Antibody titres before and after challenge





Virus isolation and PCR* results in oral swabs








*Moonen et al 2003

Virus isolation and PCR results in nasal swabs




Potency test with A/MAY/97 vaccine

- A/MAY/97 emergency vaccine (>6 PD₅₀)
- 3 groups with 5 cattle (full, 1/3, 1/9th dose)
- Challenged IDL 21 dpv with A/IRN/22/2015 by IDL
- PD₅₀/dose ~ 6.47 ($p < 0.001$, Fischer exact test)




Antibody titres in different groups before and after challenge – A/IRN/22/2015





Viraemia

Number of cattle showing viraemia
(measured by viral RNA in serum)





Virus RNA in oral swabs



No difference between groups; $p > 0.05$

Virus RNA in nasal secretions



No difference between groups; $p > 0.05$

Conclusions

- r-value is not an accurate predictor of protection with emergency vaccines
- Good correlation between heterologous antibody titres and protection
- Clinical protection was seen in the absence of detectable abs on the day of challenge
- Nasal and oral swabs were positive as soon as 1 dpc and remained positive for at least 7 dpc – good diagnostic samples
- Potency test:
 - No significant differences in virus excretion and viraemia despite differences in vaccine antigen load, but there were differences in clinical outcome
- A good quality A Malaysia 97 vaccine protects against A/Asia/G-VII
- Pre-existing natural and vaccine-induced immunity to A/ASIA/Sea-97 could be a possible explanation why the A/ASIA/G-VII lineage has not been identified so far in the South East Asia

**IMPROVED SURVEILLANCE, PREPAREDNESS AND RETURN TO TRADE FOR
EMERGENCY ANIMAL DISEASE INCURSIONS USING FOOD AND MOUTH DISEASE AS A MODEL**

PROJECT PARTNERS



This project is supported by Meat and Livestock Australia, through funding from the Australian Government Department of Agriculture and Water Resources as part of its Rural R&D for Profit programme, and by producer levies from Australian FMD-susceptible livestock (cattle, sheep, goats and pigs) industries and Charles Sturt University, leveraging significant in-kind support from the research partners.

The research partners for this project are the Commonwealth Science and Industrial Research Organisation (CSIRO), Charles Sturt University, the Bureau of Meteorology and the Australian Department of Agriculture and Water Resources, supported by Animal Health Australia (AHA).

CSIRO HEALTH & BIOSECURITY / AUSTRALIAN ANIMAL HEALTH LABORATORY

www.csiro.au



Thank you

Acknowledgements

Ryan Waters – TPI
Animal care staff at WBVR
Lab staff at WBVR

Transboundary Animal Disease Mitigation Team

CSIRO HEALTH & BIOSECURITY / AUSTRALIAN ANIMAL HEALTH LABORATORY

Wilna Vosloo
Principal Research Scientist

t +61 3 5227 5015

e wilna.vosloo@csiro.au

CSIRO HEALTH & BIOSECURITY / AUSTRALIAN ANIMAL HEALTH LABORATORY

www.csiro.au

